According to the World Health Organization around 300 million people around the world have depression. At present switching antidepressants, increasing dosages, allowing more time for medications to work, augmented medication for other conditions, neuro-stimulation and psychotherapy are some of the ways for resistant depression treatment. However, burgeoning demand to counter the therapeutic challenge resulted in the emergence of innovative resistant depression treatment. Recently ketamine-based depression treatments are gaining preference as major biopharmaceutical companies receive a green signal from the Food and Drug Administration (FDA).
Rise in demand for antidepressant treatment due to increasing mental health issues. Burden on the healthcare system due to nonresponding patients to a combination of antidepressants. Ageing population as well as increased anxiety and depression syndrome in the millennials. Ineffectiveness of antidepressants due to an individual’s genetic composition. Exposure to addictive substances that prevent antidepressant medications to positively treat patients. Stigma related to depressive disorder treatments, patent expiration, fear of drug withdrawals, high cost, lack of substantial clinical trials to gauge the efficacy of resistant depression medicines contribute as the major restraints to the global resistant depression treatment market.
High prevalence of depression and mental disorders with substantial treatment resistance in Europe and North America are indicative of progressive growth of the market. Increasing awareness about mental health and related treatments are anticipated to create greater opportunities in the near future amongst the emerging nations in the Asia-Pacific and rest of the world.